Herbal Medicine


Copenhagen - Danish medical tycoon Erik Sprunk-Jansen, former CEO of the pharmaceutical company Lundbeck A/S, started an ambitious venture to create a global company for herbal medicine by buying worldwide rights to 25 herbal medical products with extensive clinical and practical documentation. ”The 25 products all come from traditional Arabic medicine. They work on various diseases such as men's infertility, psoriasis, acne and increased cholesterol. These illnesses strike millions of people around the world,” said biochemist Dr. Stephen Fulder, a leading expert within herbal medicine. Ten years ago traditional Arabic medicine was about to be forgotten. But then a group of Palestinian researchers in Israel formed a company called Antaki to revive the tradition on a scientific basis. The 25 products are the first results of this research and scientific tests of 300 herbs and plants from the Mediterranean and the Middle East. Prognoses for sales of natural products are promising with surging consumer demands for herbal medicine. Another reason is increasing costs for development of synthetic medicine. Sprunk-Jansen A/S will enter the Danish market at the end of the year and the Baltic countries in early 2005. Poland and the other Nordic countries will follow in 2005 and 2006. Licensing agreements will be made in the most promising markets, such as the USA, Russia, Japan and Asia.



Bagsvaerd/Bangalore – Danish Novozymes A/S has begun a new collaboration with Indian Sea6 Energy. The companies will jointly develop enzymes to convert seaweed-based carbohydrates to sugar, which can then be fermented to produce...



Prague/Turku/Copenhagen – Danish pharmaceutical company H. Lundbeck A/S yesterday unveiled clinical data on its potential blockbuster drug nalmefene at the 2012 European Congress of Psychiatry clinical in Prague. While Lundbeck...



Copenhagen – With the in vitro proof of concept for an undisclosed antibody target, Genmab A/S has reached the second milestone in its collaboration with H. Lundbeck A/S. Genmab will now receive a €1m payment. Under the...



Copenhagen/Bangalore – Biofuels need reliable sources of biomass. Novozymes now looks to the ocean to secure biomass. The Danish enzyme specialist announced an exploratory research agreement with Sea6 Energy from India. The...



Copenhagen – Hellsinn Healthcare has successfully completed a phase Ib trial in Europe with Zealand Pharma’s GLP-2 (glucagone-like peptide 2) peptide antagonist Elsiglutide (ZP1846). The completion of the study, which was...



Copenhagen - An alliance of giants will take a thorough look into biofuels for the maritime sector. The leading enzyme producer Novozymes will team up with parts of the Danish shipping industry, including the world’s largest...



Copenhagen/Paris – Danish biopharma­ceuticals company Zealand Pharma A/S has received some positive news. Ever since French partner Sanofi Aventis submitted a marketing authorisation application for Lyxumia (lixisenatide) in...



Copenhagen/Paris - The cooperation between Danish biopharmaceutical company Zealand Pharma and French drugmaker Sanofi has borne its first fruit. Sanofi has submitted a marketing authorisation application for Lyxumia...



Copenhagen/Ingelheim – Danish HTS expert Nuevolution A/S has signed a license agreement with drugmaker Boeh­ringer Ingelheim (BI). The German pharma company will use Nuevolution’s proprietary Chemetics drug discovery technology...



Bagsværd - Novo Nordisk is investing around €134m in a new corporate centre in the Copenhagen suburb Bagsværd. The new office premises will concentrate the top management and 1,100 administrative employees which are currently...

Displaying results 1 to 10 out of 194

1-10 Next >

© 2007-2015 BIOCOM


All Events


Product of the week


Current issue

All issues